

This abstract was submitted to the DTRF Research Workshop in September, 2020.

AL102, Oral Gamma-Secretase Inhibitor for the Treatment of Patients Living with Desmoid Tumors

Chen Duksin, MD, MBA, Executive Medical Director, Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for patients living with rare and aggressive cancers.

Our development approach is predicated on identifying and addressing tumorigenic drivers of cancer. Our current portfolio of product candidates targets the aberrant activation of the Notch pathway with Gamma Secretase Inhibitors (GSI).

AL102, a potent, selective, and oral GSI was originally developed by BMS and licensed by Ayala along with a parenteral GSI. It is being developed for the treatment of patients with Desmoid Tumors. We will present and discuss pre-clinical and clinical data for AL102.